Alnylam LNP delivery platform receives NoA from USPTO
The patent application includes 30 claims covering composition of matter and formulations of MC3, as well as methods of using these compositions and formulations. This second generation LNP
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The neglected tropical diseases include Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Under the collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing